Day 039 - 20 Oct 94 - Page 03
1 if you give an indication that maybe more references will
2 not be needed or maybe some references will be.
3
4 MR. JUSTICE BELL: Yes, I will do that. Do not expect me ----
5
6 MR. MORRIS: We obviously do not want to go through hundreds of
7 references; I do not intend to.
8
9 MR. JUSTICE BELL: I am quite prepared to do that. You start on
10 Sunset Yellow.
11
12 MR. MORRIS (To the witness): Is there anything else,
13 Dr. Millstone? Did you manage to do a little bit of
14 preparation last night for today in terms of extracting the
15 important ----
16 A. What I have endeavoured to do is to highlight within
17 the text of the document I prepared what I take to be the
18 most salient aspects of it.
19
20 Q. Right. What I am going to do, just so we can get a system
21 going, is take you through each compound. I am going to
22 ask you first specifically on intolerances, generally
23 intolerances, and allergies, secondly, on carcinogenicity
24 and, thirdly, hyperactivity -- obviously they are not going
25 to apply to every compound -- just so we have a system of
26 knowing which evidence deals with which of those points; is
27 that OK?
28 A. Well, Mr. Morris, you are free to ask any questions you
29 think fit and I will endeavour to answer them. I would
30 like to point out, however, that not all of the adverse
31 effects to which I have endeavoured to draw attention in my
32 text fall under those headings.
33
34 Q. What is the other category -- is there another category?
35 A. If you want, the broadest way of characterising it, it
36 would be other generalised adverse effect. I mean, some
37 are typically chronic but not necessarily carcinogenic.
38
39 MR. RAMPTON: I do not know whether it does help at this stage;
40 it might help me to follow the evidence (possibly also your
41 Lordship) if, when we are talking about chronic effects, a
42 distinction is to be made, Dr. Millstone might be careful
43 to distinguish between potential chronic effects in humans
44 and observed chronic effects in animals. It may be an
45 important distinction; I do not know.
46
47 MR. JUSTICE BELL: Yes. The other thing we can do, if you like,
48 as we come to each one, I will tell you which parts I have
49 underlined in that section which appear to me to relate to
50 human beings. It does not mean to say I am neglecting
51 studies which have been done on animals, but where there is
52 a reference which appears to have been an observed or
53 indicated adverse reaction so far as men or women are
54 concerned; and in two instances which I have looked at
55 where it seems to me that the reference may not support the
56 statement made in the statement, I will canvas that with
57 you. I do not want to embark on cross-examination with
58 Dr. Millstone myself. That is not my function. In any
59 event Mr. Rampton is going to ask him such questions as he
60 sees fit to ask in due course, but I will raise it so you
